{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:51:34Z","timestamp":1791323494071,"version":"4.3.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.09.021","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:00:21Z","timestamp":1790060421000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["LNP-formulated dbDNA vaccines elicit durable humoral and cellular immunity with distinct kinetics to mRNA in non-human primates"],"prefix":"10.1016","author":[{"given":"Helen","family":"Horton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Cunliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Wane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6936-7137","authenticated-orcid":false,"given":"Lisa J.","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Tregoning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.09.021_bib1","series-title":"The Clinical Progress of mRNA Vaccines and Immunotherapies","author":"Barbier","year":"2022"},{"key":"10.1016\/j.ymthe.2026.09.021_bib2","series-title":"Revolutionizing Immunization: A Comprehensive Review of mRNA Vaccine Technology and Applications","author":"Leong","year":"2025"},{"key":"10.1016\/j.ymthe.2026.09.021_bib3","series-title":"Immunology of RNA-Based Vaccines: The Critical Interplay between Inflammation and Expression","author":"Tregoning","year":"2025"},{"key":"10.1016\/j.ymthe.2026.09.021_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115340","article-title":"A comprehensive comparison of DNA and RNA vaccines","volume":"210","author":"Wang","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.09.021_bib5","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.09.021_bib6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.021_bib7","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S1473-3099(25)00236-1","article-title":"Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial","volume":"25","author":"Chalkias","year":"2025","journal-title":"Lancet. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.09.021_bib9","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ymthe.2026.09.021_bib11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.09.021_bib12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib13","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine","volume":"26","author":"Choi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.09.021_bib14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib15","article-title":"DNA-encoded individualized neoantigen vaccines elicit durable and functional immune responses","author":"Weinert","year":"2025","journal-title":"CIMT"},{"key":"10.1016\/j.ymthe.2026.09.021_bib16","author":"Krauss"},{"key":"10.1016\/j.ymthe.2026.09.021_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.PLAS-0028-2014","article-title":"Using Plasmids as DNA Vaccines for Infectious Diseases","volume":"2","author":"Tregoning","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ymthe.2026.09.021_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00262-017-2111-y","article-title":"Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model","volume":"67","author":"Allen","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.09.021_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/gt.2014.37","article-title":"Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines","volume":"21","author":"Walters","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.09.021_bib20","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2015.1022008","article-title":"Novel synthetic plasmid and DoggyboneTM DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice","volume":"11","author":"Scott","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2026.09.021_bib21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/vaccines10071104","article-title":"SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model","volume":"10","author":"Mucker","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2026.09.021_bib22","series-title":"DNA Vaccines: History, Molecular Mechanisms and Future Perspectives","author":"Pagliari","year":"2023"},{"key":"10.1016\/j.ymthe.2026.09.021_bib23","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.021_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/1469-0691.12553","article-title":"A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation","volume":"20","author":"Hooper","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ymthe.2026.09.021_bib25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymeth.2006.05.022","article-title":"Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases","volume":"40","author":"Fuller","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.ymthe.2026.09.021_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56729-6","article-title":"DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1\/2 study assessing efficacy, safety, and immunogenicity of INO-3107","volume":"16","author":"Morrow","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.021_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-18-1763","article-title":"Immunotherapy targeting HPV16\/18 generates potent immune responses in HPV-associated head and neck cancer","volume":"25","author":"Aggarwal","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.09.021_bib28","article-title":"Immune therapy targeting E6\/E7 oncogenes of human paillomavirus type 6 (Hpv-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis","volume":"8","author":"Aggarwal","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2026.09.021_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/2051-1426-3-S2-P426","article-title":"Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results","volume":"3","author":"Aggarwal","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.09.021_bib30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.021_bib31","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and Immunogenicity of an Anti\u2013Zika Virus DNA Vaccine \u2014 Preliminary Report","volume":"385","author":"Tebas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal SynCon\u00ae Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.09.021_bib33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0264-410X(00)00302-9","article-title":"Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine","volume":"19","author":"Roy","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.09.021_bib34","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.021_bib35","doi-asserted-by":"crossref","first-page":"155ra138","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/mt.2014.245","article-title":"Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals","volume":"23","author":"Morrow","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.021_bib37","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.021_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-22-1987","article-title":"Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","volume":"29","author":"Aggarwal","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.09.021_bib39","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.09.021_bib40","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib41","article-title":"Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity","volume":"6","author":"Tursi","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101169","article-title":"Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters","volume":"32","author":"Liao","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.09.021_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2281733","article-title":"Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models","volume":"19","author":"Andrade","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2026.09.021_bib44","doi-asserted-by":"crossref","first-page":"301ra132","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib45","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates","volume":"84","author":"Geisbert","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00684-8","article-title":"The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever","volume":"4","author":"Andrade","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1589584","article-title":"Intramuscular DNA vaccine provides protection in non-human primate and mouse models of SARS-CoV-2","volume":"16","author":"Sood","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib48","article-title":"A therapeutic hepatitis b virus dna vaccine induces specific immune responses in mice and non-human primates","volume":"9","author":"De Pooter","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2026.09.021_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-024-02211-8","article-title":"Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity","volume":"24","author":"Chai","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.09.021_bib50","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1038\/s41598-020-65059-0","article-title":"Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines\/Immunoprophylaxis in Animals Including Transchromosomic Bovines","volume":"10","author":"Mucker","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.09.021_bib51","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib52","article-title":"The type I IFN-IL-27 axis promotes mRNA vaccine-induced CD8+ T cell responses","author":"Phan","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2026.09.021_bib53","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1126\/scitranslmed.abn8057","article-title":"Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection","volume":"14","author":"Evans","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109762","article-title":"The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses","volume":"255","author":"F\u00f6hse","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib55","article-title":"The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice","volume":"11","author":"Zhang","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2026.09.021_bib56","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cell.2019.04.012","article-title":"Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance","volume":"177","author":"Cirelli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.09.021_bib57","doi-asserted-by":"crossref","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","article-title":"Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination","volume":"113","author":"Tam","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.021_bib58","doi-asserted-by":"crossref","first-page":"45.27","DOI":"10.4049\/jimmunol.182.Supp.45.27","article-title":"Rapid and systemic innate immune responses to an adenoviral HIV vaccine (45.27)","volume":"182","author":"Andersen-Nissen","year":"2009","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.ymthe.2026.09.021_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2430826","article-title":"Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity","volume":"21","author":"Stirling","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2026.09.021_bib60","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.021_bib61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.09.021_bib62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib63","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib64","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/discim\/kyad030","article-title":"Optimizing a linear \u2018Doggybone\u2019 DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen","volume":"3","author":"Cunliffe","year":"2024","journal-title":"Discov. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.945706","article-title":"Comparative immunogenicity of an mRNA\/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques","volume":"13","author":"Valentin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib67","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.cell.2022.03.024","article-title":"Vaccine protection against the SARS-CoV-2 Omicron variant in macaques","volume":"185","author":"Chandrashekar","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.09.021_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.021_bib69","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.021_bib70","article-title":"BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2","author":"Vogel","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2026.09.021_bib71","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.molimm.2009.11.003","article-title":"A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition","volume":"47","author":"Liu","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib72","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.09.021_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149335","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.09.021_bib74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ymthe.2026.09.021_bib75","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fimmu.2018.00126","article-title":"Mouse models of influenza infection with circulating strains to test seasonal vaccine efficacy","volume":"9","author":"Groves","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.021_bib76","doi-asserted-by":"crossref","DOI":"10.3791\/55833","article-title":"An optimized hemagglutination inhibition (HI) assay to quantify influenzaspecific antibody titers","author":"Kaufmann","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ymthe.2026.09.021_bib77","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.vaccine.2011.04.023","article-title":"Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms","volume":"29","author":"Donnelly","year":"2011","journal-title":"Vaccine"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:12:12Z","timestamp":1791321132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626007914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"alternative-id":["S1525001626007914"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.021","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LNP-formulated dbDNA vaccines elicit durable humoral and cellular immunity with distinct kinetics to mRNA in non-human primates","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}